Clinical Trial Detail

NCT ID NCT02745769
Title A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

mantle cell lymphoma

colorectal cancer

Therapies

Merestinib + Ramucirumab

Abemaciclib + Ramucirumab

Age Groups: adult

No variant requirements are available.